Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 4,017 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 4,017 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $40.01, for a total value of $160,720.17. Following the completion of the transaction, the insider directly owned 87,715 shares of the company’s stock, valued at approximately $3,509,477.15. This represents a 4.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Castle Biosciences Stock Up 2.9%

CSTL stock opened at $42.15 on Friday. The stock has a market cap of $1.23 billion, a P/E ratio of -93.67 and a beta of 1.06. The stock’s fifty day simple moving average is $39.03 and its two-hundred day simple moving average is $28.11. The company has a current ratio of 6.47, a quick ratio of 6.31 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 1-year low of $14.59 and a 1-year high of $43.01.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.32. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. The firm had revenue of $80.55 million during the quarter, compared to analyst estimates of $71.06 million. Analysts expect that Castle Biosciences, Inc. will post 0.44 EPS for the current year.

Hedge Funds Weigh In On Castle Biosciences

Hedge funds have recently added to or reduced their stakes in the company. Schroder Investment Management Group grew its stake in shares of Castle Biosciences by 8.6% during the 2nd quarter. Schroder Investment Management Group now owns 648,572 shares of the company’s stock valued at $13,198,000 after acquiring an additional 51,483 shares during the period. Advisors Capital Management LLC boosted its position in shares of Castle Biosciences by 21.9% in the second quarter. Advisors Capital Management LLC now owns 245,867 shares of the company’s stock worth $5,021,000 after purchasing an additional 44,180 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Castle Biosciences in the third quarter worth $615,000. Squarepoint Ops LLC raised its position in shares of Castle Biosciences by 29.1% during the 2nd quarter. Squarepoint Ops LLC now owns 125,719 shares of the company’s stock valued at $2,567,000 after purchasing an additional 28,359 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Castle Biosciences by 6.2% during the 2nd quarter. Geode Capital Management LLC now owns 689,926 shares of the company’s stock valued at $14,090,000 after buying an additional 40,073 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CSTL has been the subject of several recent analyst reports. Zacks Research downgraded shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 2nd. Weiss Ratings reiterated a “sell (d)” rating on shares of Castle Biosciences in a research report on Monday, December 29th. Robert W. Baird raised their price target on Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 4th. Guggenheim raised their target price on shares of Castle Biosciences from $30.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Finally, Lake Street Capital increased their price target on shares of Castle Biosciences from $35.00 to $52.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $46.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.